Does Early Graft Patency Benefit from Perioperative Statin Therapy? A Propensity Score-Matched Study of Patients Undergoing Off-Pump Coronary Artery Bypass Surgery

Background. Decreased graft patency after off-pump coronary artery bypass grafting (OPCAB) leads to substantial increases in cardiac events. However, there is paucity of data on efficacy and safety of perioperative statin therapy for OPCAB populations. Methods. 582 patients undergoing OPCAB in a sin...

Full description

Saved in:
Bibliographic Details
Main Authors: Shanglin Chen, Hengchao Wu, Tao Yang, Baotong Li, Yuanyu Hu, Hansong Sun
Format: Article
Language:English
Published: Wiley 2019-01-01
Series:Cardiovascular Therapeutics
Online Access:http://dx.doi.org/10.1155/2019/1582183
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850161384703131648
author Shanglin Chen
Hengchao Wu
Tao Yang
Baotong Li
Yuanyu Hu
Hansong Sun
author_facet Shanglin Chen
Hengchao Wu
Tao Yang
Baotong Li
Yuanyu Hu
Hansong Sun
author_sort Shanglin Chen
collection DOAJ
description Background. Decreased graft patency after off-pump coronary artery bypass grafting (OPCAB) leads to substantial increases in cardiac events. However, there is paucity of data on efficacy and safety of perioperative statin therapy for OPCAB populations. Methods. 582 patients undergoing OPCAB in a single-institution database (October 1, 2009–September 30, 2012) were stratified by perioperative continuation of statin therapy (CS group, n=398) or not (DS group, n=184). Inverse probability weighted propensity adjustment was used to account for treatment assignment bias, resulting in a well-matched cohort. Primary outcomes were graft patency at an average of five days after operation and in-hospital mortality. Secondary outcomes included intraoperative blood loss, liver, and renal functions. Results. No in-hospital death occurred in this study. Early graft patency rates after OPCAB were 98.4% (1255 of 1275 grafts) in the CS group and 98.0% (583 of 595 grafts, P=0.486) in the DS group. Secondary outcomes showed a reduction in blood loss during operation (438.53 mL versus 480.47 mL, P=0.01). Continuation of statin therapy is associated with alanine transaminase (ALT) elevation (49.67 U/L versus 34.52 U/L, P<0.001), as well as aspartate transaminase (33.54 U/L versus 28.10 U/L, P<0.001). Abnormal ALT elevation was observed in 8.9% of the CS group and 3.1% in DS (odds ratio 3.06, 95% confidence interval, 1.77 to 5.29, P<0.001). There was no significant difference in estimated glomerular filtration rate (76.28 mL/min/1.73m2 versus 76.13 mL/min/1.73m2, P=0.90). Subgroup analyses suggested that graft occlusion was less common in CS than in DS group among smoking patients (odds ratio 0.41, 95% confidence interval, 0.20 to 0.86, P=0.026). Conclusions. Perioperative continuation of statin therapy did not improve early graft patency in OPCAB patients. A lower risk of graft occlusion was observed among smoking patients. Continuous statin use correlated with liver function elevation (Clinical Trials.gov number, NCT 01268917).
format Article
id doaj-art-fff491dfa2e747bb95a111af090353dc
institution OA Journals
issn 1755-5914
1755-5922
language English
publishDate 2019-01-01
publisher Wiley
record_format Article
series Cardiovascular Therapeutics
spelling doaj-art-fff491dfa2e747bb95a111af090353dc2025-08-20T02:22:50ZengWileyCardiovascular Therapeutics1755-59141755-59222019-01-01201910.1155/2019/15821831582183Does Early Graft Patency Benefit from Perioperative Statin Therapy? A Propensity Score-Matched Study of Patients Undergoing Off-Pump Coronary Artery Bypass SurgeryShanglin Chen0Hengchao Wu1Tao Yang2Baotong Li3Yuanyu Hu4Hansong Sun5Department of Cardiac Surgery, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, ChinaDepartment of Cardiac Surgery, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, ChinaDepartment of Cardiac Surgery, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, ChinaDepartment of Cardiac Surgery, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, ChinaDepartment of Cardiac Surgery, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, ChinaDepartment of Cardiac Surgery, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, ChinaBackground. Decreased graft patency after off-pump coronary artery bypass grafting (OPCAB) leads to substantial increases in cardiac events. However, there is paucity of data on efficacy and safety of perioperative statin therapy for OPCAB populations. Methods. 582 patients undergoing OPCAB in a single-institution database (October 1, 2009–September 30, 2012) were stratified by perioperative continuation of statin therapy (CS group, n=398) or not (DS group, n=184). Inverse probability weighted propensity adjustment was used to account for treatment assignment bias, resulting in a well-matched cohort. Primary outcomes were graft patency at an average of five days after operation and in-hospital mortality. Secondary outcomes included intraoperative blood loss, liver, and renal functions. Results. No in-hospital death occurred in this study. Early graft patency rates after OPCAB were 98.4% (1255 of 1275 grafts) in the CS group and 98.0% (583 of 595 grafts, P=0.486) in the DS group. Secondary outcomes showed a reduction in blood loss during operation (438.53 mL versus 480.47 mL, P=0.01). Continuation of statin therapy is associated with alanine transaminase (ALT) elevation (49.67 U/L versus 34.52 U/L, P<0.001), as well as aspartate transaminase (33.54 U/L versus 28.10 U/L, P<0.001). Abnormal ALT elevation was observed in 8.9% of the CS group and 3.1% in DS (odds ratio 3.06, 95% confidence interval, 1.77 to 5.29, P<0.001). There was no significant difference in estimated glomerular filtration rate (76.28 mL/min/1.73m2 versus 76.13 mL/min/1.73m2, P=0.90). Subgroup analyses suggested that graft occlusion was less common in CS than in DS group among smoking patients (odds ratio 0.41, 95% confidence interval, 0.20 to 0.86, P=0.026). Conclusions. Perioperative continuation of statin therapy did not improve early graft patency in OPCAB patients. A lower risk of graft occlusion was observed among smoking patients. Continuous statin use correlated with liver function elevation (Clinical Trials.gov number, NCT 01268917).http://dx.doi.org/10.1155/2019/1582183
spellingShingle Shanglin Chen
Hengchao Wu
Tao Yang
Baotong Li
Yuanyu Hu
Hansong Sun
Does Early Graft Patency Benefit from Perioperative Statin Therapy? A Propensity Score-Matched Study of Patients Undergoing Off-Pump Coronary Artery Bypass Surgery
Cardiovascular Therapeutics
title Does Early Graft Patency Benefit from Perioperative Statin Therapy? A Propensity Score-Matched Study of Patients Undergoing Off-Pump Coronary Artery Bypass Surgery
title_full Does Early Graft Patency Benefit from Perioperative Statin Therapy? A Propensity Score-Matched Study of Patients Undergoing Off-Pump Coronary Artery Bypass Surgery
title_fullStr Does Early Graft Patency Benefit from Perioperative Statin Therapy? A Propensity Score-Matched Study of Patients Undergoing Off-Pump Coronary Artery Bypass Surgery
title_full_unstemmed Does Early Graft Patency Benefit from Perioperative Statin Therapy? A Propensity Score-Matched Study of Patients Undergoing Off-Pump Coronary Artery Bypass Surgery
title_short Does Early Graft Patency Benefit from Perioperative Statin Therapy? A Propensity Score-Matched Study of Patients Undergoing Off-Pump Coronary Artery Bypass Surgery
title_sort does early graft patency benefit from perioperative statin therapy a propensity score matched study of patients undergoing off pump coronary artery bypass surgery
url http://dx.doi.org/10.1155/2019/1582183
work_keys_str_mv AT shanglinchen doesearlygraftpatencybenefitfromperioperativestatintherapyapropensityscorematchedstudyofpatientsundergoingoffpumpcoronaryarterybypasssurgery
AT hengchaowu doesearlygraftpatencybenefitfromperioperativestatintherapyapropensityscorematchedstudyofpatientsundergoingoffpumpcoronaryarterybypasssurgery
AT taoyang doesearlygraftpatencybenefitfromperioperativestatintherapyapropensityscorematchedstudyofpatientsundergoingoffpumpcoronaryarterybypasssurgery
AT baotongli doesearlygraftpatencybenefitfromperioperativestatintherapyapropensityscorematchedstudyofpatientsundergoingoffpumpcoronaryarterybypasssurgery
AT yuanyuhu doesearlygraftpatencybenefitfromperioperativestatintherapyapropensityscorematchedstudyofpatientsundergoingoffpumpcoronaryarterybypasssurgery
AT hansongsun doesearlygraftpatencybenefitfromperioperativestatintherapyapropensityscorematchedstudyofpatientsundergoingoffpumpcoronaryarterybypasssurgery